Advertisement

PharmacoEconomics

, Volume 31, Issue 8, pp 663–675 | Cite as

Overview of Parametric Survival Analysis for Health-Economic Applications

  • K. Jack Ishak
  • Noemi Kreif
  • Agnes Benedict
  • Noemi Muszbek
Review Article

Abstract

Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric survival analysis methods can be applied to identify an appropriate statistical model for the observed data, which can then be extrapolated to derive a complete time-to-event curve. This paper describes the properties of the most commonly used statistical distributions as a basis for these models and describes an objective process of identifying the most suitable parametric distribution in a given dataset. The approach can be applied with both individual-patient data as well as with survival probabilities derived from published Kaplan–Meier curves. Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial.

Keywords

Overall Survival Sorafenib Survival Probability Individual Patient Data Accelerate Failure Time Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported in part by a grant from Bayer HealthCare Pharmaceuticals to United BioSource Corporation. The authors are employees of United BioSource Corporation. Bayer HealthCare Pharmaceuticals reviewed and commented on this manuscript, but final editorial control was retained by the authors. KJI was responsible for the development of methods, oversaw analyses, and led the drafting and finalizing of the paper; NK carried out analyses, drafted parts of the paper, and reviewed drafts; AB and NM drafted parts of the paper and reviewed drafts.

References

  1. 1.
    Cuzick J, Sestak I, Baum M, et al, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–1141.Google Scholar
  2. 2.
    Tappenden P, Chilcott J, Ward S, et al. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006;42:2867–75.CrossRefPubMedGoogle Scholar
  3. 3.
    Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics. 2005;23(4):323–32.CrossRefPubMedGoogle Scholar
  4. 4.
    Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://www.nicedsu.org.uk.
  5. 5.
    Collett D. Modelling survival data in medical research. 2nd ed. London: Chapman & Hall/CRC; 2003.Google Scholar
  6. 6.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Berlin: Springer; 2005.Google Scholar
  8. 8.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–81.CrossRefGoogle Scholar
  9. 9.
    Siegel S. Non-parametric statistics for the behavioral sciences. New York: McGraw-Hill; 1956. p. 75–83.Google Scholar
  10. 10.
    Cox DR. Regression models and life-tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187–220.Google Scholar
  11. 11.
    Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRefPubMedGoogle Scholar
  12. 12.
    Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.CrossRefPubMedGoogle Scholar
  13. 13.
    StataCorp LP. STATA survival analysis and epidemiological tables. Reference manual, release 12. College Station: Stata Press; 2011.Google Scholar
  14. 14.
    Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9. doi: 10.1186/1471-2288-12-9.CrossRefPubMedGoogle Scholar
  15. 15.
    Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004;7(5):627–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Bebbington M, Lai CD, Zitikis R. Modeling human mortality using mixtures of bathtub shaped failure distributions. J Theor Biol. 2007;245(3):528–38.CrossRefPubMedGoogle Scholar
  17. 17.
    Gray RJ. Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Statist Assn. 1992;87(420):942–951.Google Scholar
  18. 18.
    Royston P, Parmar MKB. Flexible parametric-hazards and proportional odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.Google Scholar
  20. 20.
    Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):article 34.Google Scholar
  21. 21.
    Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009;172:383–404.CrossRefPubMedGoogle Scholar
  22. 22.
    Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak KJ, Ross P. Modeling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28(7):1141–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Castelli C, Combescure C, Foucher Y, et al. Cost-effectiveness analysis in colorectal cancer using a semi-Markov model. Stat Med. 2007;26(30):5557–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Shiroiwa T, Fukuda T, Shimozuma K, et al. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109(3):559–66.CrossRefPubMedGoogle Scholar
  26. 26.
    Soini EJ, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.CrossRefPubMedGoogle Scholar
  27. 27.
    Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008;12(15):ii–ix, xi–162.Google Scholar
  28. 28.
    Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1–184, iii–iv.Google Scholar
  29. 29.
    Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • K. Jack Ishak
    • 1
  • Noemi Kreif
    • 2
  • Agnes Benedict
    • 3
  • Noemi Muszbek
    • 3
  1. 1.United BioSource CorporationDorvalCanada
  2. 2.London School of Hygiene and Tropical MedicineLondonUK
  3. 3.United BioSource CorporationLondonUK

Personalised recommendations